Nos

0

essais cliniques ouverts

Vous êtes patient : votre médecin est à votre disposition pour vous expliquer si votre pathologie vous rend eligible à un essai.

Qu’est ce qu’un essai clinique ?

Plus d’informations via l’INCa

Vous êtes médecin : Vous avez un patient éligible à l’un de ces essais ? Nous vous invitons à joindre le contact indiqué pour chaque essai.

Date de mise à jour : Décembre 2021

PAR
LOCALISATION
TUMORALE

NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03517449 Lenvatinib in Combination With   Pembrolizumab Versus Treatment of Physician’s Choice in Participants With   Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard   Convention [KEYNOTE-775]) 3 Endometrial Neoplasms Critères advanced, recurrent or metastatic 2 jerome.alexandre@aphp.fr Cochin
NCT03745950 UTOLA: UTerin OLAparib (UTOLA 2 Endometrial Cancer MSI-High, MMR, POLE, FGFR
mutations
alterations
Critères advanced/metastatic 2 jerome.alexandre@aphp.fr Cochin
NCT04463771 Safety and Efficacy of   Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in   Participants With Advanced or Metastatic Endometrial Cancer Who Have   Progressed on or After Platinum-based Chemotherapy. 2 Endometrial Cancer Critères Advanced or Metastatic 2 jerome.alexandre@aphp.fr Cochin
NCT04634877 Study of Pembrolizumab (MK-3475)   in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in   Participants With Newly Diagnosed Endometrial Cancer After Surgery With   Curative Intent 3 Endometrial Neoplasms Critères newly diagnosed 1 jerome.alexandre@aphp.fr Cochin
NCT03469674 PORTEC-4a: Molecular   Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer 3 Endometrial Cancer Critères Stage I, Stage II catherine.durdux@aphp.fr HEGP
NCT02866370 Study Of Nintedanib Compared To   Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or   Endometrium (NiCCC) 2 Ovarian Clear Cell   Carcinoma
     Endometrial Clear Cell Carcinoma
Critères Progressive or recurrent >ou= 2 bruno.borghese@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT04246489 Bintrafusp Alfa Monotherapy in   Platinum-Experienced Cervical Cancer 2 Uterine Cervical Neoplasms Critères advanced unresectable and/or metastatic 1,2 bruno.borghese@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03693170 Phase II, open-label, single   arm, multicenter study of encorafenib, binimetinib plus cetuximab in subjects   with previously untreated BRAF V600E   -mutant Metastatic Colorectal Cancer 2 CCRm Critères métastatique 1 romain.coriat@aphp.fr Cochin
NCT04163887 Effect of the Laparoscopic   Approach in Reducing Postoperative Severe Complications Following Hepatectomy   for Colorectal Liver Metastases (METALAP) Non Applicable / Chirurgie Métastase hépatique de cancer du   colon Critères Metastatique david.fuks@aphp.fr Cochin
NCT02355379 Randomised phase III trial   evaluating adjuvant chemotherapy after the stage III colon adenocarcinoma   resection for patient of 70 year old or more 3 Cancer du colon Critères Adjuvant/Stage III Adjuvant Julien Taieb : jtaieb75@gmail.com HEGP
NCT02945033 Study on Aspirin Versus Placebo   in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk (ASPIK   French) 3 Cancer du colon PI3K Critères Adjuvant/Stage II-III Adjuvant Julien Taieb : jtaieb75@gmail.com HEGP
NCT02967289 A Phase III, Randomised,   international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for   high- risk stage III colon cancer in adjuvant setting
     
3 Cancer du colon Critères Adjuvant/Stage III Adjuvant Julien Taieb : jtaieb75@gmail.com HEGP
NCT03164655 A randomized phase II study   comparing treatment intensification with hepatic arterial infusion   chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in   patients with liver-only colorectal metastases considered still non   resectable after at least two months of systemic induction chemotherapy:   SULTAN (improving SUrgery of Liver metastases: a Trial of the Arterial   chemotherapy Network) 2 Cancer du colon Critères Métastases hépatiques 2 Julien Taieb : jtaieb75@gmail.com HEGP
NCT03829462 A randomized phase III trial   assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib   alone in metastatic colorectal cancer patients after failure of standard   therapies, according to the A/A genotype of Cyclin D1 3 Cancer du colon génotype A/A (rs9344) de la cycline D1   
     
     
Critères Métastatique ≥2 Julien Taieb :   jtaieb75@gmail.com HEGP
NCT04034459 FOLFOXIRI Plus Cetuximab vs.   FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC 2 Cancer du colon BRAF muté (V600E). RAS wt Critères Métastatique 1 Julien Taieb :   jtaieb75@gmail.com HEGP
NCT04120701 Circulating tumor dna based   decision for adjuvant treatment in colon cancer stage II
     

     
3 Cancer du colon Critères Adjuvant/Stage II- Adjuvant Julien Taieb : jtaieb75@gmail.com HEGP
NCT04262687 PEMBROLIZUMAB ASSOCIE AU XELOX   BEVACIZUMAB CHEZ LES PATIENTS AVEC UN CANCER COLORECTAL METASTATIQUE   MICROSATELLITE STABLE (MSS) ET UN FORT INFILTRAT IMMUNITAIRE : ETUDE PREUVE   DE CONCEPT (POCHI) 2 Cancer du colon Critères Métastatique 1 Julien Taieb : jtaieb75@gmail.com HEGP
NCT04450836 Sequences Of REGorafenib And   Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer   (SOREGATT) 2 Cancer du colon Critères Métastatique ≥2 Julien Taieb :   jtaieb75@gmail.com HEGP
NCT04456699 A Phase 3 Randomized, Open-label   Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination   With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with   Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following   First-line Induction of FOLFOX With Bevacizumab (LYNK-003)
     
3 Cancer du colon Critères Métastatique 1 Julien Taieb :   jtaieb75@gmail.com HEGP
NCT04737187 Phase III study of   trifluridine/tipiracil in combination with bevacizumab vs   trifluridine/tipiracil single agent in patients with refractory metastatic   colorectal cancer 3 Cancer du colon Critères Métastatique 2,3 Julien Taieb :   jtaieb75@gmail.com HEGP
NCT02885753 Systemic Oxaliplatin or   Intra-arterial Chemotherapy Combined With LV5FU2 and an Target Therapy in   First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver   (OSCAR) 3 Cancer du colon Critères Métastases hépatiques 1 Julien Taieb : jtaieb75@gmail.com et   romain.coriat@aphp.fr HEGP/Cochin
NCT03186326 Standard Chemotherapy vs   Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer   (SAMCO) 2 Cancer du colon MSI Critères Métastatique 2 Julien Taieb : jtaieb75@gmail.com et   romain.coriat@aphp.fr HEGP/Cochin
NCT03584711 A Phase II Study Evaluating   FOLFOX + Panitumumab According to a « Stop and go » Strategy With a   Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance   Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma   Without a RAS Mutation 2 Cancer du colon RAS wt; BRAF wt Critères Métastatique 1 Julien Taieb : jtaieb75@gmail.com et   romain.coriat@aphp.fr HEGP/Cochin
NCT04392479 TWICE-IRI: Optimization of   second-line therapy with aflibercept, irinotecan (day 1 or day 1,3),   5-Fluorouracile and folinic acid in patients with metastatic colorectal   cancer. A randomized Phase III study.
     
3 Cancer du colon Critères Métastatique 2 Julien Taieb : jtaieb75@gmail.com et   romain.coriat@aphp.fr HEGP/Cochin
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02924376 Efficacy and Safety of   Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable   Cholangiocarcinoma Who Failed Previous Therapy – (FIGHT-202) 2 Cholangiocarcinoma FGFR2 Critères >ou= 2 romain.coriat@aphp.fr Cochin
NCT03630640 Neoadjuvant and Adjuvant   Nivolumab in HCC Patients Treated by Electroporation (NIVOLEP) 2 Hepatocellular Carcinoma Critères 2 stanislas.pol@aphp.fr Cochin
NCT03773302 Phase 3 Study of BGJ398 (Oral   Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene   Fusions/Translocations 3 Cholangiocarcinoma FGFR2 fusions/translocations Critères unresectable locally advanced or   metastatic 1 romain.coriat@aphp.fr Cochin
NCT04163900 Comparing NUC-1031 Plus   Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary   Tract Cancer 3 Biliary Tract Cancer Critères locally advanced, unresectable or   metastatic 1 ou 2 romain.coriat@aphp.fr Cochin
NCT04791735 Value of the Laparoscopic   Approach in the Surgical Management of Resectable Hepatocellular Carcinoma   (LapCHC) Non Applicable / Chirurgie Hepatocellular Carcinoma Critères david.fuks@aphp.fr Cochin
NCT03364530 Hepatic Arterial Infusion of   Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic   Unresectable Intra-hepatic Cholangiocarcinoma 2 Intra-hepatic Cholangiocarcinome Critères Non résecable-Non Métastatique 2 Julien Taieb :   jtaieb75@gmail.com HEGP
NCT03656536 A Study to Evaluate the Efficacy   and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic   Cholangiocarcinoma 3 Cholangiocarcinome Réarrangement FGFR2 Critères LA-Métastatique 1 Julien Taieb :   jtaieb75@gmail.com HEGP
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02997358 Study Comparing Efficacy of   Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in   Patients With Leiomyosarcoma (LMS04) 3 Soft Tissue Leiomyosarcoma Critères metastatic or relapsed 1 jerome.alexandre@aphp.fr Cochin
NCT03692065 API-CAT STUDY for APIxaban   Cancer Associated Thrombosis (API-CAT) 3 Cancer-associated Thrombosis –   in gastro cancer Critères tout stade toute ligne romain.coriat@aphp.fr Cochin
NCT04268121 Efficacy of Neoadjuvant   Chemotherapy in Terms of DFS in Patients With Localized Digestive   Neuroendocrine Carcinomas (NEONEC)
     
2 Neuroendocrine Carcinoma in   gastro Critères localized neoadjuvant romain.coriat@aphp.fr Cochin
NCT04282590 A Study to Investigate the   Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN   (Chopin Study) 2 Chemotherapy-induced Peripheral   Neuropathy – in Gastro cancer Critères 2 romain.coriat@aphp.fr Cochin
NCT04325425 Chemotherapy For Metastatic   Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of   GastroEnteroPancreatic And Unknown Primary (FOLFIRINEC) 2 Neuroendocrine Carcinoma in   gastro Critères Grade 3 or high grade MiNEN 1 romain.coriat@aphp.fr Cochin
NCT02260505 A randomized, multicentre, Phase   III trial evaluating the interest of imatinib treatment maintenance or   interruption after 3 years of adjuvant treatment in patients with   Gastrointestinal Stromal Tumours (GIST) 3 GIST KIT positivity Critères Adjuvant Adjuvant Julien Taieb : jtaieb75@gmail.com HEGP
NCT03362177 Study of Romiplostim for   Chemotherapy-induced Thrombocytopenia in Adult Subjects With   Gastrointestinal, Pancreatic, or Colorectal Cancer 3 Chemotherapy-induced   Thrombocytopenia Critères All Julien Taieb :   jtaieb75@gmail.com HEGP
NCT02820857 Assessment of the Efficacy of   Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients   Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine   Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer 2 tumeur neuroendocrine Critères LA-Métastatique 2 Julien Taieb : jtaieb75@gmail.com et   romain.coriat@aphp.fr HEGP/Cochin
NCT03351296 Randomized phase 2 trial of two   chemotherapy regimens plus or minus bevacizumab in patients with well   differentiated pancreatic neuroendocrine tumors 2 tumeur neuroendocrine du   pancréas Critères LA-Métastatique 1 Julien Taieb : jtaieb75@gmail.com et   romain.coriat@aphp.fr HEGP/Cochin
NCT03591731 A GCO trial exploring the   efficacy and safety of Nivolumab monotherapy or Nivolumab plus Ipilimumab in   pre-treated patients with advanced, refractory pulmonary or   gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) 2 tumeur neuroendocrine Critères LA-Métastatique 2,3 Julien   Taieb : jtaieb75@gmail.com / romain.coriat@aphp.fr /   francoise.lepimpec-barthes@aphp.fr HEGP/Cochin
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02502370 Phase III Trial Investigating   the Potential Benefit of Adjvant Chemotherapy for Small Bowel   Adenocarcinoma 3 INTESTIN GRELE Critères Adjuvant Adjuvant Julien Taieb : jtaieb75@gmail.com HEGP
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03719924 Nal-iri/lv5-fu Versus Paclitaxel   as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell   Carcinoma 3 Carcinome Epidermoïde de   l’oesophage Critères Métastatique 2 Julien Taieb :   jtaieb75@gmail.com HEGP
NCT03722108 Regorafenib Combined With   Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal   Adenocarcinomas 2 Adénocaecinome   oeso-gastrique Critères Métastatique 2 Julien Taieb :   jtaieb75@gmail.com HEGP
NCT03748134 Sintilimab or Placebo With   Chemotherapy in Esophageal Squamous Cell Carcinoma 3 Carcinome Epidermoïde de   l’oesophage Critères LA-Métastatique 1 Julien Taieb :   jtaieb75@gmail.com HEGP
NCT03783442 A Study of Tislelizumab   (BGB-A317) in Combination With Chemotherapy as First Line Treatment in   Participants With Advanced Esophageal Squamous Cell Carcinoma 3 Esophageal Squamous Cell   Carcinoma (ESCC) Critères Unresectable, locally advanced   recurrent or metastatic 1 Julien Taieb : jtaieb75@gmail.com HEGP
NCT03959293 Clinical Trial Evaluating   FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line   Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction   Adenocarcinoma 2 Adénocaecinome   oeso-gastrique Critères Métastatique 2 Julien Taieb :   jtaieb75@gmail.com HEGP
NCT04006262 Peri-operative Association of   Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab,   Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI)   and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma 2 Adénocaecinome   oeso-gastrique dMMR et/ou MSI Critères Péri-op Péri-op Julien Taieb :   jtaieb75@gmail.com HEGP
NCT04543617 A Study of Atezolizumab With or   Without Tiragolumab in Participants With Unresectable Esophageal Squamous   Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive   Concurrent Chemoradiotherapy 3 Carcinome Epidermoïde de   l’oesophage Critères LA 1 Julien Taieb :   jtaieb75@gmail.com HEGP
NCT04592913 A Randomized, Double-blind,   Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and   FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable   Gastric and Gastroesophageal Junction Cancer (GC/GEJC) (Matterhorn) 3 Adénocarcinome   oeso-gastrique Critères Péri-op Péri-op aziz.zaanan@aphp.fr HEGP
NCT04704934 A Phase 3, Multicenter, 2-Arm   Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With   HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal   Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a   Trastuzumab-Containing Regimen (DESTINY-Gastric04) 3 Adénocaecinome oeso-gastrique HER2 positif Critères LA-Métastatique 2 aziz.zaanan@aphp.fr HEGP
NCT04732494 A Phase 2, Multicenter,   Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy of   Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Plus Anti-TIGIT   Monoclonal Antibody BGB-A1217 Versus Tislelizumab Plus Placebo as Second-Line   Treatment in Patients With PD-L1 vCPS ≥ 10% Unresectable, Locally Advanced,   Recurrent or Metastatic Esophageal Squamous Cell Carcinoma   (BGB-A317-A1217-203) 2 Carcinome Epidermoïde de   l’oesophage Critères LA-Métastatique 2 aziz.zaanan@aphp.fr HEGP
NCT03006432 Phase III randomised trial to   evaluate FOLFOX with or without docetaxel (TFOX) as 1st line chemotherapy for   locally advanced or metastatic oesophago-gastric carcinoma 3 Adénocaecinome   oeso-gastrique HER-2 négative Critères Métastatique 1 Julien Taieb : jtaieb75@gmail.com et   romain.coriat@aphp.fr HEGP/Cochin
NCT03760822 Second-Line Chemotherapy With   Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal   Junction Cancer Patients 2 Adénocaecinome   oeso-gastrique Critères Métastatique 2 Julien Taieb : jtaieb75@gmail.com et   romain.coriat@aphp.fr HEGP/Cochin
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02313389 Maintenance Treatment Versus   Observation in Elderly Patients With PCNS Lymphoma (BLOCAGE-01) 3 Primary Central Nervous System   Lymphoma Critères newly diagnosed 1 didier.bouscary@aphp.fr Cochin
NCT02619630 Multicenter Study of   Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)   (GRAALL-2014/T) 2 T-cell Adult Acute Lymphoblastic   Leukemia Critères 1 didier.bouscary@aphp.fr Cochin
NCT03993912 Compare Lenalidomide and   Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects   With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose   Therapy (IFM2017_03) 3 Multiple Myeloma Critères 1 didier.bouscary@aphp.fr Cochin
NCT02416388 Study to Improve OS in 18 to 60   Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin   Induction Regimens, High Dose Versus Intermediate Dose Cytarabine   Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in   Allografted Patients in First CR (BIG-1) 2,3 Acute Myeloid Leukemia (AML) Critères newly diagnosed de novo or   secondary type AML 1 didier.bouscary@aphp.fr,   felipe.suarez@aphp.fr Cochin/Necker
NCT02283775 A Phase 1b Study of SAR650984   (Isatuximab) in Combination With Pomalidomide and Dexamethasone for the   Treatment of Relapsed/Refractory Multiple Myeloma 1 myeloma Critères laurent.frenzel@aphp.fr Necker
NCT03249870 A Phase 2 Study of Inotuzumab   Ozogamicin (INO) Combined to Chemotherapy in Older Patients With Philadelphia   Chromosome-negative CD22+ B-cell Precursor Acute Lymphoblastic Leukemia 2 Leukemia Critères felipe.suarez@aphp.fr Necker
NCT03366272 Nivolumab With Gemcitabine,   Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients (NIVEAU) 3 lymphoma Critères david.sibon@aphp.fr Necker
NCT03503409 IDH1 (AG 120) Inhibitor in   Patients With IDH1 Mutated Myelodysplastic Syndrome 2 Myélodysplasie Critères felipe.suarez@aphp.fr Necker
NCT03836014 A Multi-center Phase III   Randomized Study Comparing Continuous Versus Fixed Duration Therapy With   Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma 3 Multiple Myeloma Critères laurent.frenzel@aphp.fr Necker
NCT03839771 A Study of Ivosidenib or   Enasidenib in Combination With Induction Therapy and Consolidation Therapy,   Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute   Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2   Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML) 3 Leukemia Critères ambroise.marcais@aphp.fr Necker
NCT03871829 A Phase 2 Study of Daratumumab   Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and   Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in   Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab   to Evaluate Daratumumab 2 Multiple Myeloma Critères laurent.frenzel@aphp.fr Necker
NCT04002297 Study Comparing Zanubrutinib +   Rituximab Versus Bendamustine + Rituximab in Participants With Untreated   Mantle Cell Lymphoma 3 lymphoma Critères olivier.hermine@aphp.fr Necker
NCT04027309 A Study of Gilteritinib Versus   Midostaurin in Combination With Induction and Consolidation Therapy Followed   by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid   Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations   Eligible for Intensive Chemotherapy (HOVON 156 AML) 3 Leukemia Critères ambroise.marcais@aphp.fr Necker
NCT04531046 Axi-Cel as a 2nd Line Therapy in   Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to   Autologous Stem Cell Transplantation 2 Lymphoma Critères morgane.cheminant@aphp.fr Necker
NCT04554914 An Open-label, Single-arm,   Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel   in Subjects With Epstein-Barr Virus-associated Diseases 2 EBV associated diseases Critères felipe.suarez@aphp.fr Necker
NCT04688983 An Open Label, 3-arm, Randomised   Phase II Study to Compare the Safety and Efficacy of Ponatinib in Combination   With Either Chemotherapy or Blinatumomab With Imatinib Plus Chemotherapy as   Front-line Therapy for Patients Aged 55 Years and Over With Philadelphia   Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL) 2 leukemia Critères ambroise.marcais@aphp.fr Necker
NCT04751877 Multicenter Open Label Phase 3   Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without   Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant   Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years) 3 Multiple Myeloma Critères laurent.frenzel@aphp.fr Necker
NCT04984837 Study of Lacutamab in Peripheral   T-cell Lymphoma 2 lymphoma Critères morgane.cheminant@aphp.fr Necker
NTC04703192 Valemetostat Tosylate   (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for   Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) 2 lymphoma Critères olivier.hermine@aphp.fr Necker
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02215265 reduced intensity adjuvant treatment in   patients undergoing transoral surgery for Human papillomavirus (HPV)-positive   oropharyngeal cancer (PATHOS) 3 Carcinome épidermoïde de   l’oropharynx HPV-induit Critères operable, locally advanced Adjuvant haitham.mirghani@aphp.fr HEGP
NCT03765918 Study of Pembrolizumab Given   Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for   Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) 3 Cancer ORL PDL1 Critères Advanced pré/post-op audrey.simonaggio@aphp.fr HEGP
NCT04398524 A Phase II Study of cemiplimab ,   an anti PD 1
     monoclonal antibody, and ISA101b vaccine in patients with   recurrent/metastatic HPV16 positive Oropharyngeal Cancer who have experienced   disease progression with prior anti PD 1 therapy
2 Cancer ororpharyngé HPV16 HPV16 positive Critères Récidivant / Métastatique >1 haitham.mirghani@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02866370 Study Of Nintedanib Compared To   Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or   Endometrium (NiCCC) 2 Ovarian Clear Cell   Carcinoma
     Endometrial Clear Cell Carcinoma
Critères Progressive or recurrent >ou= 2 bruno.borghese@aphp.fr Cochin
NCT03249142 Immunotherapy With Neo-adjuvant   Chemotherapy for OVarian Cancer (INeOV) 1,2 ovarian cancer,fallopian tube Critères newly diagnosed 1 jerome.alexandre@aphp.fr Cochin
NCT03752216 NIraparib and Quality Of LifE is   a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.   (NiQoLe) 4 Ovarian Cancer Critères high grade epithelial ovarian   cancer 2 jerome.alexandre@aphp.fr Cochin
NCT04209855 A Study of Mirvetuximab   Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant,   Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube   Cancers With High Folate Receptor-Alpha Expression (MIRASOL) 3 Epithelial Ovarian Cancer
     Peritoneal Cancer
     Fallopian Tube Cancer
Critères high-grade 2 bruno.borghese@aphp.fr Cochin
NCT04641247 A randomized, double-blindphase 3 comparison of   platinum-based therapy with TSR-042 and Niraparib versus standard of care   platinum-based therapy as first-line treatment of stage 3 or 4 non mucinous   epithelial ovarian cancer (TESARO FIRST) 3 Epithelial Ovarian Cancer Critères jerome.alexandre@aphp.fr Cochin
NCT03353831 Atezolizumab in combination with   bevacizumab and chemotherapy versus bevacizumab and chemotherapy in
     early relapse Ovarian cancer
3 Ovarian Cancer Critères jerome.alexandre@aphp.fr,   nicolas.delanoy@aphp.fr Cochin/HEGP
NCT03598270 Platinum-based Chemotherapy With   Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA) 3 Ovarian Carcinoma Critères high- grade serous or   endometrioid ovarian, primary peritoneal or tubal carcinoma 1,2,3 bruno.borghese@aphp.fr,   franne-sophie.bats@aphp.fr Cochin/HEGP
NCT03353832 Atezolizumab in combination with   Bevacizumab and Chemotherapy
     versus Bevacizumab and Chemotherapy
     in recurrent ovarian cancer (AGO-OVAR 2.29)
3 cancer épithélial de l’ovaire,   des trompes de Fallope ou du péritoine Critères      Metastatic >1 <4 nicolas.delanoy@aphp.fr HEGP
NCT03579394 Retarded Surgery Following   Neoadjuvant Chemotherapy in Advanced Ovarian Cancer (CHRONO) 3 Ovarian Cancer Critères Stage III, IV 1 anne-sophie.bats@aphp.fr HEGP
NCT03602859 A Phase 3 Comparison of   Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care   (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV   Nonmucinous Epithelial Ovarian Cancer (FIRST) 3 Ovarian Cancer Critères Stage III, IV 1 nicolas.delanoy@aphp.fr HEGP
NCT03737643 Durvalumab Treatment in   Combination With Chemotherapy and Bevacizumab, Followed by Maintenance   Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer   Patients. 3 Advanced Ovarian Cancer Critères advanced (Stage III-IV) 1 anne-sophie.bats@aphp.fr HEGP
NCT03842982 Hyperthermic Intraperitoneal   Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) 3 Ovarian Cancer Critères Stage III 2 anne-sophie.bats@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02676349 Neoadjuvant mFolfirinox With or   Without Preoperative Concomitant Chemoradiotherapy in Patients With   Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) 2 Pancreatic Carcinoma Critères Borderline resectable status neoadjuvant romain.coriat@aphp.fr Cochin
NCT02959879 Neo-adjuvant FOLF(IRIN)OX for   Resectable Pancreatic Adenocarcinoma (PANACHE01) 2 Pancreatic Duct Adenocarcinoma Critères Resectable adenocarcinoma neoadjuvant romain.coriat@aphp.fr Cochin
NCT03679169 Evaluation of Complete   microscopicE Resection Margin (R0) and Lymph Node Involvement After Standard   Pancreatosplenectomy (SPS) Versus Radical Anterograde Modular   Pancreatosplenectomy (REMIND-01) Non Applicable / Chirurgie Cancer du pancréas Critères Invasive resectable david.fuks@aphp.fr Cochin
NCT04083235 A Study to Assess the   Effectiveness and Safety of Irinotecan Liposome Injection,   5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated   for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine   Treatment (NAPOLI 3)A Study to Assess the Effectiveness and Safety of   Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in   Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to   Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3) 3 Adenocarcinoma of the Pancreas Critères metastatic 1 romain.coriat@aphp.fr Cochin
NCT04348045 Phase II Study to Evaluate   MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to   BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic   Adenocarcinoma Patients (D19-02) 2 Adénocarcinome du Pancreas BRCA / KRASS Critères Métastatique 1 Julien Taieb :   jtaieb75@gmail.com HEGP
NCT03693677 First Line Metastatic Pancreatic   Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen   of 2 Months 5FU/LV+Nal-IRI 2 Adénocarcinome du Pancreas Critères Métastatique 1 Julien Taieb :   jtaieb75@gmail.com et romain.coriat@aphp.fr HEGP/Cochin
NCT04167007 FOLFOX vs Gemcitabine in   Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX 3 Adénocarcinome du Pancreas Critères Métastatique 1 Julien Taieb : jtaieb75@gmail.com et   romain.coriat@aphp.fr HEGP/Cochin
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02760498 Study of REGN2810 in Patients   With Advanced Cutaneous Squamous Cell Carcinoma 2 Carcinome épidermoïde cutané   avancé Critères locally advanced or metastatic 1,2 selim.aractingi@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03977194 Atezolizumab in Elderly Patients   With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel   Chemotherapy (ELDERLY) 3 Cancer du poumon non à petites   cellules (NSCLC) Critères metastatic 1 marie.wislez@aphp.fr Cochin
NCT02912949 A Study of Zenocutuzumab   (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion 1,2 : First in human tumeurs solides / NSCLC / cancer   du pancréas NRG1 Fusion NRG1 fusion Critères 2 marie.wislez@aphp.fr Cochin
NCT03447769 Study of Efficacy and Safety of   Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8   II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer   (Canopy-A) 3 Cancer du poumon non à petites   cellules (NSCLC) Critères IIA-IIIA and IIIB (atteintes   résiduelles N2 seulement) 2 marie.wislez@aphp.fr Cochin
NCT03924869 Efficacy and Safety Study of   Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475)   in Adults With Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC)   (MK-3475-867/KEYNOTE-867) 3 Cancer du poumon non à petites   cellules (NSCLC) Critères I or IIA 1 marie.wislez@aphp.fr Cochin
NCT03940703 A Study of Tepotinib Plus   Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) 2 Cancer du poumon non à petites   cellules (NSCLC) MET Amplified, EGFR Critères Locally advanced or metastatic 2 marie.wislez@aphp.fr Cochin
NCT03968419 This Study Will Evaluate the   Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination   as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N) 2 Cancer du poumon non à petites   cellules (NSCLC) Critères Stade IB-IIIA 1 marie.wislez@aphp.fr Cochin
NCT04026412 A Study of Nivolumab and   Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer   (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) 3 Cancer du poumon non à petites   cellules (NSCLC) Critères Locally advanced stage IIIA,   IIIB, or IIIC (T1-2 N2-3 M0, T3 N1-3 M0, or T4 N0-3 M0) 1 marie.wislez@aphp.fr Cochin
NCT04111705 Lorlatinib After Failure of   First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced   ALK-positive Non-small Cell Lung Cancer (ORAKLE) 2 Cancer du poumon non à petites   cellules (NSCLC) ALK rearrangement Critères locally advanced or metastatic   (Stage IIIB or IV ) 2 marie.wislez@aphp.fr Cochin
NCT04233021 Study of Osimertinib in Patients   With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation   (ORBITAL) 2 Cancer du poumon non à petites   cellules (NSCLC) EGFR Critères metastatic (Leptomeningeal   &
     Brain)
2, 3 or 4 marie.wislez@aphp.fr Cochin
NCT04475939 Placebo-controlled Study   Comparing Niraparib Plus Pembrolizumab Versus Placebo and Pembrolizumab as   Maintenance Therapy (ZEAL-1L) 3 Cancer du poumon non à petites   cellules (NSCLC) Without known alteration Critères Advanced (Stage IIIB not amenable   to definitive chemoradiotherapy) or metastatic (Stage IV) 2 marie.wislez@aphp.fr Cochin
NCT04526782 ENCOrafenib With Binimetinib in   bRAF NSCLC (ENCO-BRAF) 2 Cancer du poumon non à petites   cellules (NSCLC) BRAF Critères Stage IV 2 marie.wislez@aphp.fr Cochin
NCT04547504 PEmbRolizumab verSus   chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With   PDL1 ≥ 50 % (PERSEE) 3 Cancer du poumon non à petites   cellules (NSCLC) PDL1 (expression >50%) Critères Stage IV or . Unresectable and   non-eligible to radiotherapy stage III 1 marie.wislez@aphp.fr Cochin
NCT04624204 Placebo-controlled, Study of   Concurrent Chemoradiation Therapy With Pembrolizumab Followed by   Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage   Small Cell Lung Cancer (LS-SCLC) 3 Cancer du poumon à petites   cellules (SCLC) Critères locally (Limited-Stage SCLC   (Stage I-III) 1 marie.wislez@aphp.fr Cochin
NCT04621188 Lorlatinib After Failure of   First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) 2 Non-Small Cell Lung Cancer Critères marie.wislez@aphp.fr Cochin
NCT04623775 Study of Relatlimab plus   Nivolumab in combination with chemotherapy vs.Nivolumab in combination with   chemotherapy 2 Non-Small Cell Lung Cancer Critères Stage IV or recurrent 1 marie.wislez@aphp.fr Cochin
NCT04746924 A Study of Ociperlimab With   Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung   Cancer 3 lung cancer Critères marie.wislez@aphp.fr Cochin
NCT04940325 Datopotamab (DS-1062a) in   advanced and/or unresectable non-small   lung cancer 2 Non-Small Cell Lung Cancer Critères Avanced and/or unresectable 2 et plus marie.wislez@aphp.fr Cochin
NCT04956692 Study of Pembrolizumab (MK-3475)   Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With   Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or   Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) 3 lung cancer Critères marie.wislez@aphp.fr Cochin
NCT04194944 A Study of Selpercatinib   (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive   Non-Small Cell Lung Cancer (LIBRETTO-431) 3 Cancer du poumon non à petites   cellules (NSCLC) Ret-fusion Critères Advanced or metastatic : Stage   IIIB-IIIC or Stage IV 1 marie.wislez@aphp.fr /   francoise.lepimpec-barthes@aphp.fr Cochin/HEGP
NCT03178552 A Study to Evaluate Efficacy and   Safety of Multiple Targeted Therapies as Treatments for Participants With   Non-Small Cell Lung Cancer (NSCLC) (B-FAST 2,3 Non-Small Cell Lung Cancer Critères Unresectable stage IIIB or   IV >1 francoise.lepimpec-barthes@aphp.fr HEGP
NCT03833154 Durvalumab vs Placebo With   Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell   Lung Cancer Patients (PACIFIC-4) 3 Carcinoma, Non-Small-Cell Lung Critères Stage I to II NSCLC francoise.lepimpec-barthes@aphp.fr HEGP
NCT03976375 Efficacy and Safety of   Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in   Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and   Progressive Disease (PD) After Platinum Doublet Chemotherapy and   Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) 3 Cancer du poumon non à petites   cellules (NSCLC) Critères metastatic (Stage IV: M1a, M1b,   M1c) 2 jacques.medioni@aphp.fr HEGP
NCT04154956 SAR408701 Versus Docetaxel in   Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5   (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer   Patients (CARMEN-LC03) 3 Cancer du poumon non à petites   cellules (NSCLC) CEACAM5 positive Critères metastatic 2 jacques.medioni@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03458247 Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer (OPTIMABI) 2 Prostate cancer Critères jerome.alexandre@aphp.fr Cochin
NCT02566772 Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer 1,2 Prostate cancer Critères 1 ou 4 stephane.oudard@aphp.fr HEGP
NCT03395197 Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2) 3 Metastatic Castration-Resistant Prostate Cancer (mCRPC) Critères Metastatic 2 stephane.oudard@aphp.fr HEGP
NCT04100018 A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer (CheckMate 7DX) 3 Prostate Cancer Critères metastatic > ou = 2 stephane.oudard@aphp.fr HEGP
NCT04446117 Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02) 3 Metastatic Prostate Cancer
Prostate Adenocarcinoma
Critères 2 stephane.oudard@aphp.fr HEGP
NCT04720157 An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition) 3 Prostate cancer Critères 1 stephane.oudard@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03875781 Non inferiority multicenter   phase III randomized trial comparing preoperative chemotherapy only to   chemotherapy followed by chemoradiotherapy for locally advanced resectable   rectal cancer 2 Cancer du Rectum Critères Pré-opératoire Pré-op Julien Taieb : jtaieb75@gmail.com et   romain.coriat@aphp.fr HEGP/
Cochin
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03138512 A Study Comparing Nivolumab,   Nivolumab in Combination With Ipilimumab and Placebo in Participants With   Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney   (CheckMate 914) 3 Renal Cell Carcinoma Critères >1 stephane.oudard@aphp.fr HEGP
NCT03937219 Study of Cabozantinib in   Combination With Nivolumab and Ipilimumab in Patients With Previously   Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313) 3 Renal Cell Carcinoma Critères advanced or metastatic (AJCC   Stage IV) 1 stephane.oudard@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT04149574 A Study Comparing the Efficacy   and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG)   Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder   Cancer (HR NMIBC) (CheckMate 7G8) 3 Bladder Cancer Critères Persistent or recurrent disease >ou= 2 michael.peyromaure@aphp.fr Cochin
NCT03799835 Atezolizumab Plus One-year BCG   Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder   Cancer Patients (ALBAN) 3 Bladder Cancer Critères T1 tumor and/or
     High grade (WHO 2004) and/or
     Grade 3 (WHO1973) and/or
     Carcinoma in situ
1,2 michael.peyromaure@aphp.fr   / stephane.oudard@aphp.fr Cochin/HEGP
NCT03924895 Perioperative Pembrolizumab   (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab   Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible   Participants With Muscle-invasive Bladder Cancer 3 Bladder cancer Critères Péri-op michael.peyromaure@aphp.fr   / stephane.oudard@aphp.fr Cochin/HEGP
NCT04209114 A Study of Nivolumab Plus   Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in   Participants With Bladder Cancer That Has Invaded the Muscle Wall of the   Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder   Cancer 3 Bladder Cancer Critères muscle-invasive pré/post-op jacques.medioni@aphp.fr HEGP
NCT03549715 NEoadjuvant Dose-dense MVAC In   cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial   Carcinoma (NEMIO) 1,2 Carcinome urothélial infiltrant   de la vessie Critères invasive Adjuvant jacques.medioni@aphp.fr,
michael.peyromaure@aphp.fr
HEGP/Cochin
NCT04640623 A Study of TAR-200 in   Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in   Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to   Intravesical Bacillus Calmette-Guerin Who Are Ineligible for or Elected Not   to Undergo Radical Cystectomy (SunRISe-1) 2 high-risk Non-Muscle Invasive   Bladder Cancer Critères marc-olivier.timsit@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02389244 A Phase II Study Evaluating   Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas   (REGOBONE) 2 Bone Sarcoma Critères pascaline.boudou@aphp.fr Cochin
NCT03469804 Phase II Multicentric Study of   Pembrolizumab in Classic or Endemic Kaposi’s Sarcoma (KAPKEY) 2 Kaposi Sarcoma Critères Progressive disease >ou= 2 selim.aractingi@aphp.fr Cochin
NCT03624244 Evaluation of Clinical Impact of   Interruption VS Maintenance of AI in Patients With Locally Advanced/   Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS) (BFR-ESS) 2 Endometrial Sarcoma Critères jerome.alexandre@aphp.fr Cochin
NCT03643133 Mifamurtide Combined With   Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma   Patients (SARCOME13) 2 Osteosarcoma Critères high-grade osteosarcoma post-op pascaline.bourdou@aphp.fr Cochin
NCT03784014 Molecular Profiling of Advanced   Soft-tissue Sarcomas (MULTISARC) 3 Soft Tissue Sarcoma Critères Unresectable locally advanced   and/or metastatic STS 1 pascaline.bourdou@aphp.fr Cochin
NCT04055220 Efficacy and Safety of   Regorafenib as Maintenance Therapy After First-line Treatment in Patients   With Bone Sarcomas (REGOSTA) 2 Bone Sarcoma Critères pascaline.boudou@aphp.fr Cochin
NCT04307277 Interest of Peri Operative   CHemotherapy In Patients With CINSARC High-risk Localized Grade 1 or 2 Soft   Tissue Sarcoma (CHIC-STS01) 3 Soft tissue sarcoma Critères Resectable and localized disease Péri-op pascaline.bourdou@aphp.fr Cochin
NCT04757337 Comparison of Oral   Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft   Tissue Sarcoma Patients (GERICO14) 3 Soft tissue sarcoma Critères pascaline.boudou@aphp.fr Cochin
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03659136 The XENERA™ 1 Study Tests   Xentuzumab in Combination With Everolimus and Exemestane in Women With   Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread 2 breast cancer ER + or/and PgR + & HER2 – Critères Locally advanced or metastatic 1,2 jacques.medioni@aphp.fr HEGP
NCT03701334 A Trial to Evaluate Efficacy and   Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients   With HR+/HER2- Early Breast Cancer (NATALEE) 3 Breast cancer ER + or/and PgR + & HER2 – Critères early invasive 1 jacques.medioni@aphp.fr HEGP
NCT03809988 PALbociclib Rechallenge in   horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)   (PALMIRA) 2 breast cancer ER + or/and PgR + & HER2 – Critères Advanced 1,2 jacques.medioni@aphp.fr HEGP
NCT04109066 Study of Nivolumab Versus   Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine   Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+),   Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast   Cancer (CheckMate 7FL) 3 Breast cancer ER + and HER2 – Critères Localized invasive 1 anne-sophie.bats@aphp.fr HEGP
NCT04478266 Amcenestrant (SAR439859) Plus   Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced   Breast Cancer 2,3 Breast Cancer ER + and HER2 – Critères loco-regional recurrent or   metastatic 1 anne-sophie.bats@aphp.fr HEGP
NCT04622319 A Study of Trastuzumab   Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk   HER2-positive Participants With Residual Invasive Breast Cancer Following   Neoadjuvant Therapy (DESTINY-Breast05) 3 breast cancer HER2 + Critères Stade III 1 jacques.medioni@aphp.fr HEGP
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT03547973 Phase II Open Label, Study of   IMMU-132 in Metastatic Urothelial Cancer 2 Carcinome urothélial Critères locally advanced or localized muscle-invasive 2 michael.peyromaure@aphp.fr Cochin
NCT03390504 A Study of Erdafitinib Compared   With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced   Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene   Aberrations 3 Carcinome urothélial FGFR Critères advanced or metastatic 2,3 jacques.medioni@aphp.fr HEGP
NCT03473743 Study of Erdafitinib in   Participants With Metastatic or Locally Advanced Urothelial Cancer 1,2 Carcinome urothélial Critères metastatic or locally advanced 1,2 jacques.medioni@aphp.fr HEGP
NCT03785925 A Single-Arm Study of   Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients   Who Have Locally Advanced or Metastatic Urothelial Cancer (PIVOT-10) 2 Carcinome urothélial Critères metastatic or locally advanced 1 jacques.medioni@aphp.fr HEGP
NCT04197986 Study of Oral Infigratinib for   the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With   Susceptible FGFR3 Genetic Alterations 3 Carcinome urothélial FGFR3 Critères invasive adjuvant jacques.medioni@aphp.fr HEGP
NCT04527991 A Randomized Open-Label Phase   III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in   Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer   (TROPICS-04) 3 Carcinome urothélial Critères metatstatic or locally advanced   unresectable 3, 4, 5 constance.thibault@aphp.fr HEGP
NCT04586244 « An Open-Label, Randomized,   Phase 2, Umbrella Study of Various
     Neoadjuvant Therapies for Participants With Muscle-Invasive   Urothelial
     Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse
     Cisplatin Therapy and Undergoing Radical Cystectomy (Optimus) »
2 Cancer urothelial Critères Cisplatin-ineligible 1 constance.thibault@aphp.fr HEGP
NCT04658862 A Study of TAR-200 in   Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in   Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder   (SunRISe-2) 3 Muscle-Invasive Urothelial   Carcinoma (MIBC) Critères marc-olivier.timsit@aphp.fr HEGP
NCT03549715 NEoadjuvant Dose-dense MVAC In   cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial   Carcinoma (NEMIO) 1,2 Carcinome urothélial infiltrant   de la vessie Critères invasive Adjuvant jacques.medioni@aphp.fr /   michael.peyromaure@aphp.fr HEGP/Cochin
NCT Titre de l’essai Phase Indication Altération génétique/marqueur Critères d’inclusion Stade Ligne de traitement Contact Site d’inclusion
NCT02734004 A Phase I/II Study of MEDI4736   in Combination With Olaparib in Patients With Advanced Solid Tumors.   (MEDIOLA) 1,2 pan-tumoral (Sein, poumon,   ovaire, cancer, gastro) Critères Advanced 2 jerome.alexandre@aphp.fr Cochin
NCT03486873 Long-term Safety and Efficacy   Extension Study for Participants With Advanced Tumors Who Are Currently on   Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study 3 pan-tumoral Critères Advanced or
     Metastatic
2 francois.goldwasser@aphp.fr Cochin
NCT03822117 Efficacy and Safety of   Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically   Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or   Translocations (FIGHT-207 2 pan-tumoral FGFR genes   mutations/translocation Critères advanced or metastatic or is   surgically unresectable 2 jerome.alexandre@aphp.fr Cochin
NCT02715284 Study of TSR-042, an   Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in   Participants With Advanced Solid Tumors (GARNET) 1 pan-tumoral Critères recurrent or advanced solid tumor 2 jacques.medioni@aphp.fr HEGP
NCT03157128 Phase 1/2 Study of LOXO-292 in   Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors,   and Medullary Thyroid Cancer (LIBRETTO-001) 1,2 : First in human pan-tumoral Ret-fusion Critères locally advanced or metastatic 1,2 jacques.medioni@aphp.fr HEGP
NCT03170960 Study of Cabozantinib in   Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic   Solid Tumors 1,2 pan-tumoral Critères inoperable, locally advanced,   metastatic, or recurrent 1 ou 2 jacques.medioni@aphp.fr HEGP
NCT03899155 Pan Tumor Nivolumab Rollover   Study 2 pan-tumoral Critères jacques.medioni@aphp.fr HEGP